- Published on
Toxicology – Sulfonylurea Toxicity
Source
Sulfonylureas are oral medications used to treat diabetes by lowering blood glucose levels. They are divided into first-generation agents (e.g., chlorpropamide, tolbutamide) and second-generation agents (e.g., glipizide, glyburide, glimepiride), with the latter generally having longer durations of action.
Typical Presentation
Toxicity often occurs in children after accidental ingestion or in adults due to overdose. Patients typically present with symptoms of low blood sugar, which may be severe and prolonged.
Clinical Features
The hallmark finding is hypoglycemia, which can manifest as confusion, dizziness, sweating, nausea, vomiting, fainting, seizures, or coma. Symptoms may recur due to the long-lasting effect of these medications.
Mechanism of Action
Sulfonylureas stimulate insulin release from pancreatic beta cells. They act by blocking potassium channels on these cells, leading to membrane depolarization, opening of calcium channels, and increased insulin secretion. This results in decreased blood glucose levels.
Management
Immediate treatment involves intravenous dextrose (e.g., D50) to correct hypoglycemia. Continuous glucose monitoring and repeated glucose administration may be necessary. Octreotide (a somatostatin analog) can be used to suppress insulin release and reduce the risk of recurrent hypoglycemia. Activated charcoal may be considered in early presentations. Patients should be admitted for observation due to the risk of prolonged or recurrent symptoms.
Key Points
Source
Sulfonylureas are oral medications used to treat diabetes by lowering blood glucose levels. They are divided into first-generation agents (e.g., chlorpropamide, tolbutamide) and second-generation agents (e.g., glipizide, glyburide, glimepiride), with the latter generally having longer durations of action.
Typical Presentation
Toxicity often occurs in children after accidental ingestion or in adults due to overdose. Patients typically present with symptoms of low blood sugar, which may be severe and prolonged.
Clinical Features
The hallmark finding is hypoglycemia, which can manifest as confusion, dizziness, sweating, nausea, vomiting, fainting, seizures, or coma. Symptoms may recur due to the long-lasting effect of these medications.
Mechanism of Action
Sulfonylureas stimulate insulin release from pancreatic beta cells. They act by blocking potassium channels on these cells, leading to membrane depolarization, opening of calcium channels, and increased insulin secretion. This results in decreased blood glucose levels.
Management
Immediate treatment involves intravenous dextrose (e.g., D50) to correct hypoglycemia. Continuous glucose monitoring and repeated glucose administration may be necessary. Octreotide (a somatostatin analog) can be used to suppress insulin release and reduce the risk of recurrent hypoglycemia. Activated charcoal may be considered in early presentations. Patients should be admitted for observation due to the risk of prolonged or recurrent symptoms.
Key Points
- Even small ingestions can cause significant hypoglycemia, especially in children.
- Recurrent hypoglycemia is common due to prolonged drug action.
- Toxicity may be increased when combined with certain medications or alcohol.
- Close monitoring is essential until blood glucose levels stabilize.
0 Comments
